FDA advisory panel recommends broader legal access to six peptide therapies, citing safety and grey-market concerns

An FDA advisory panel has voted to recommend expanding legal access to six peptide therapies, according to a report published July 29, as the agency weighs how to address demand for compounded peptide products and concerns about safety risks and regulatory gaps in the marketplace.

The recommendation came from the FDA Pharmacy Compounding Advisory Committee, which, the report says, voted in favor of widening legal access to the six peptide compounds. Supporters of the move argue that expanding lawful availability could reduce reliance on non-regulated purchases that have grown during what they describe as years of federal inaction.

The report attributes the framing of the issue to American Greatness, which discussed the panel’s action in the context of grey-market sourcing. It characterizes the committee’s rationale as focused on compliance and oversight, rather than endorsing particular uses, and says the committee’s recommendation was shaped by concerns about how patients obtain these peptides when legal access is limited.

The FDA advisory panel’s deliberations, as described in the report, center on the compounding pathway that allows certain customized medications to be prepared for individual patients under regulatory rules. Expanding legal access, if adopted by the agency, would change how providers and patients are able to obtain peptide therapies through the regulated system rather than through outlets outside the federal framework.

While the report describes broadening access as a way to pull patients away from the grey market, it does not describe specific enforcement actions, investigations, or penalties that prompted the committee vote. It also does not identify the vote tally or any immediate FDA rulemaking timeline tied directly to the advisory recommendation.

FDA advisory committees are structured to provide recommendations to the agency, which retains authority over whether to adopt the committee’s guidance. Under that process, the committee’s vote is not the final regulatory decision, and FDA action would still be required to convert the recommendation into binding policy or updated regulatory standards.

According to the account, the practical effect under consideration is improved lawful availability for these six peptides, paired with oversight expected to reduce risk from products obtained outside established compounding channels. The next step is for FDA to determine how the panel’s recommendation fits with existing authorities governing compounding and drug quality, safety, and compliance.